How To Improve Post-Approval Evidence Generation
Early Scientific Advice Can Flag Up Likely Evidence Gaps
Executive Summary
A new scientific paper explains how companies can improve their post-licensing evidence generation plans by seeking scientific advice from EU regulators and health technology bodies at appropriate times during the drug development process.
You may also be interested in...
How CAR-Ts Are Changing The Lifecycle Paradigm For ATMPs
CAR T-cell therapies have resulted in the industry and regulators exploring unconventional approaches to collecting real-world safety and efficacy data from existing registries. Can this approach also work for other types of cell and gene therapy products in the future? Delegates at a conference in London explored the topic.
EU ATMP Developers Missing Out By Failing To Use Advice On Offer
Regulators and health technology assessment officials in the EU are disappointed that sponsors of advanced therapy medicinal products are not making good use of the joint scientific advice service, which can help converge regulatory and HTA requirements for these products.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.